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Abstract
Background:  There is little scientific evidence to support the usual practice of providing
outpatient rehabilitation to patients undergoing total knee replacement surgery (TKR) immediately
after discharge from the orthopaedic ward. It is hypothesised that the lack of clinical benefit is due
to the low exercise intensity tolerated at this time, with patients still recovering from the effects
of major orthopaedic surgery. The aim of the proposed clinical trial is to investigate the clinical and
cost effectiveness of a novel rehabilitation strategy, consisting of an initial home exercise
programme followed, approximately six weeks later, by higher intensity outpatient exercise classes.
Methods/Design:  In this multicentre randomised controlled trial, 600 patients undergoing
primary TKR will be recruited at the orthopaedic pre-admission clinic of 10 large public and private
hospitals in Australia. There will be no change to the medical or rehabilitative care usually provided
while the participant is admitted to the orthopaedic ward. After TKR, but prior to discharge from
the orthopaedic ward, participants will be randomised to either the novel rehabilitation strategy or
usual rehabilitative care as provided by the hospital or recommended by the orthopaedic surgeon.
Outcomes assessments will be conducted at baseline (pre-admission clinic) and at 6 weeks, 6
months and 12 months following randomisation. The primary outcomes will be self-reported knee
pain and physical function. Secondary outcomes include quality of life and objective measures of
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physical performance. Health economic data (health sector and community service utilisation, loss
of productivity) will be recorded prospectively by participants in a patient diary. This patient cohort
will also be followed-up annually for five years for knee pain, physical function and the need or
actual incidence of further joint replacement surgery.
Discussion: The results of this pragmatic clinical trial can be directly implemented into clinical
practice. If beneficial, the novel rehabilitation strategy of utilising outpatient exercise classes during
a later rehabilitation phase would provide a feasible and potentially cost-effective intervention to
optimise the physical well-being of the large number of people undergoing TKR.
Trial Registration: ACTRN12609000054213
Background
The number of total knee replacements (TKR) performed
each year is increasing rapidly in most developed coun-
tries [1-7]. In Australia, the total number of TKR opera-
tions performed has increased by 150% in the past decade
[1]. Currently the mean age of patients undergoing TKR in
Australia is 70 years, however the proportion of patients
aged less than 65 years at the time of surgery has been
increasing over the years reaching 32% in 2007 [1]. It is
anticipated that the demand for TKR surgery will at least
double again within the next decade and the average age
at surgery will continue to decrease [3,8]. This trend is not
only attributable to the aging of the population, increased
prevalence of obesity and the expectation of a 'baby
boomer' cohort less willing to accept the sedentary life-
style, but also involves factors such as the evolution in
implant design and surgical procedures resulting in better
outcomes from TKR in relatively early stages of osteoar-
thritis (OA) [9]. It is readily apparent that the public
health significance of TKR surgery is and will continue to
be sizable.
Severe symptomatic knee OA is the main indication for
almost all primary TKR surgery [1,6,9,10]. People affected
by severe symptomatic knee OA experience significant
functional limitation [11], and reduced lower limb mus-
cle strength [12], aerobic fitness [13] and quality of life
[14,15]. The need for rehabilitation following TKR is
based on the contention that these deficits do not sponta-
neously resolve after surgery [16-19].
For the majority of patients, there are marked improve-
ments after TKR in pain and physical function, with the
maximum achievable benefit appearing around 6 months
after surgery [20,21]. However, the magnitude of
improvement is smaller than that demonstrated after total
hip replacement surgery [21-23], and about 15% of
patients still report moderate to severe pain a year after
TKR despite no evidence of radiographic abnormalities
[24]. Many years after TKR, patients are left with the lower
limb muscle strength deficits evident prior to surgery [25-
27] and with imbalances between knee extensor and
flexor forces [25]. Poor ligamentous and neuromuscular
control may result in destructive mechanical stresses and
reduced control over anterior shear forces on the knee
implant, potentially limiting implant longevity. It follows
then, that muscle strengthening should be a major goal of
rehabilitation. In support of this, achievement of greater
knee extensor strength after TKR has been associated with
improved physical function [26]. Younger people (<65
years of age) demonstrate less improvement after TKR
[14] and have higher rates of revision surgery [10,28,29].
Effective rehabilitation may be particularly important in
this younger group as they require prolonged implant lon-
gevity and are more likely to be in full-time employment
or imposing greater physical demands on the knee
implant.
In Australia, rehabilitation following TKR is mostly deliv-
ered in an outpatient setting by physiotherapists [30]. This
rehabilitation commences immediately after discharge
from the acute orthopaedic ward and is usually completed
within 6 weeks, with resource-intensive one-on-one
modes of delivery more common than class-based modes.
However, evidence from randomised controlled trials sug-
gests that such outpatient rehabilitation is no more effec-
tive than no treatment [31,32] or a home exercise
programme [33,34]. One possible reason for the lack of
demonstrable benefit is that the evaluated exercise pro-
grams did not specifically monitor or progress training
intensity [31-34]. However training intensity is unlikely to
be able to be progressed sufficiently to achieve meaning-
ful changes in muscle strength in the first few weeks after
TKR when patients are still experiencing the anaemia,
pain and oedema inevitably associated with recovery from
major orthopaedic surgery.
In support of our hypothesis, a recent trial provided initial
evidence that a supervised exercise programme commenc-
ing two months after TKR resulted in improved function
and reduced pain compared to a home exercise pro-
gramme [35]. The clinical benefits were evident both at
the end of the treatment period and six months after TKR.
Apart from timing, another noticeable difference betweenBMC Musculoskeletal Disorders 2009, 10:69 http://www.biomedcentral.com/1471-2474/10/69
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this rehabilitation programme and those evaluated in
other clinical trials was that the training intensity was
closely monitored and each exercise had varying difficulty
and complexity to allow progression. However, the reha-
bilitation programme was delivered on an individual
basis so was resource-intensive.
The aim of the proposed clinical trial is to compare, the
long-term effectiveness of a novel rehabilitation strategy
versus current usual rehabilitative care received after dis-
charge from the orthopaedic ward in patients who have
undergone primary TKR. The novel rehabilitation strategy
consists of an initial home exercise programme during the
early recovery period followed by two months of outpa-
tient exercise classes. A health economic evaluation,
undertaken from the perspectives of the health sector and
society, will be conducted alongside this clinical trial. We
hypothesise that the novel rehabilitation strategy will lead
to greater gains in physical well-being and be more cost-
effective than usual care.
Methods
The MARKER (Maximum Recovery after Knee Replace-
ment) Study is a multicentre randomised controlled trial
that will be conducted in 10 large public and private hos-
pitals in Australia. Participants will be required to provide
written informed consent prior to starting the study. Eth-
ics approval has been obtained from the University of
Sydney Human Research Ethics Committee and from the
Ethics Review Committee (RPAH Zone) of the Sydney
South West Area Health Service using the National Ethics
Application Form https://www.neaf.gov.au/. The
MARKER Study has been registered at the Australian and
New Zealand Clinical Trials Registry
(ACTRN12609000054213).
Potential participants will be screened and recruited at the
orthopaedic pre-admission clinic. Inclusion criteria are:
(i) aged between 45 to 74 years, (ii) planned unilateral or
bilateral primary TKR, and (iii) able to be discharged
home from the orthopaedic ward. Exclusion criteria
include: (i) previous unicompartmental replacement or
tibial osteotomy on the same knee, (ii) previous lower
limb joint replacement surgery within the last six months,
(iii) further lower limb joint replacement surgery antici-
pated within the next 12 months, (iv) major co-morbidity
precluding aerobic exercise at 50–60% maximum heart
rate, (v) rheumatoid arthritis, (vi) major neurological
conditions, or (vii) inability to return to one of the partic-
ipating sites for outpatient exercise classes.
There will be no change to usual medical or rehabilitative
care during the peri-operative inpatient period. After TKR,
but before discharge from the orthopaedic ward, partici-
pants will be randomly allocated to either the novel reha-
bilitation strategy or usual rehabilitative care specific for
the orthopaedic centre or surgeon (control group). The
randomisation schedule will be generated a priori using a
computer generated random number sequence by an
independent researcher with no participant contact, in
varying blocks of four or six, and stratified by recruitment
site and by unilateral or bilateral TKR. Allocations will be
sealed in opaque and consecutively numbered envelopes
with a clear audit trail.
Interventions
Novel rehabilitation strategy
Stage 1: Initial home exercise programme (usually Week 1
to 6 after randomisation)
Participants will be provided with a written home exercise
programme on discharge from acute care (Additional file
1). The exercises will focus on maintaining and improving
active knee flexion and extension range of motion. Partic-
ipants will repeat the exercises 5 to 10 times per exercise,
three times daily. Participants' progress, including adher-
ence to the home exercise programme, walking ability and
knee symptoms (e.g. pain, wound healing, range of
motion, swelling), will be monitored weekly by a research
physiotherapist, with clinic visits in the first one or two
weeks and by telephone calls thereafter.
Stage 2: Outpatient exercise classes (usually Week 6 to 14
after randomisation)
Approximately five weeks after randomisation, the
research physiotherapist will commence screening during
the weekly telephone calls to assess eligibility to com-
mence the classes: (i) surgical wound healed, (ii) full
weight-bearing tolerated on the operated limb, (iii)
ambulating independently outdoors for more than 50 m,
and (iv) not requiring daily opioid-based analgesics for
knee pain. Participants will join the outpatient exercise
classes as they become eligible.
The classes will be circuit-based and supervised by a phys-
iotherapist. The one hour classes will be conducted twice
a week. Participants will be encouraged to attend the
ongoing classes for eight weeks. Each class will consist of
a short warm up and cool down component, progressive
functional and strengthening exercises, and a 20-minute
monitored aerobic exercise session on a stationary bicycle
(Additional file 1). In order to standardise this pro-
gramme across centres, minimal equipment will be used
and supervising physiotherapists will receive prior train-
ing from research staff as well as a written manual of pro-
cedures. Participants will record the loads, repetitions and
sets for to each functional and strengthening exercise they
complete, and the duration and exertion (maximal heart
rate or the Borg Rating of Perceived Exertion Scale [36])BMC Musculoskeletal Disorders 2009, 10:69 http://www.biomedcentral.com/1471-2474/10/69
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for the aerobic exercise, in an exercise diary during the
classes.
At the beginning of each exercise class, knee pain, range of
motion and swelling will be evaluated to allow appropri-
ate exercise progression. To allow this level of monitoring,
class size will be restricted to a maximum of six partici-
pants. An education class will be provided once a month
focusing on the rationale for increasing lower limb muscle
strength and beneficial lifestyle behaviours appropriate
after TKR. In addition, participants will be required to do
at least one additional intensive exercise session per week
at home, consisting of 30 minutes of walking outdoors or
stationary bicycle.
Control group
Participants in the control group will receive the usual
rehabilitation management as recommended by their
orthopaedic surgeon or provided by the hospital, and can
be delivered in the inpatient or outpatient setting. Find-
ings from a previous Australian national survey demon-
strate that rehabilitation will usually commence
immediately after discharge from the orthopaedic ward,
be completed within 6 to 8 weeks after TKR and will be
provided on an individual basis by a physiotherapist in
the outpatient setting [30]. Rehabilitation received by the
control group will be documented in the patient diary.
Outcomes assessments
Assessments will be conducted at baseline (pre-admission
clinic), and 6 weeks, 6 months and 12 months after ran-
domisation by assessors blinded to treatment allocation.
Demographic information collected at baseline will
include height, weight, socioeconomic data (highest level
of education completed, health insurance status, employ-
ment status, occupation), history of lower limb arthritis
and joint surgery and the 19-item Hospital for Special Sur-
gery Knee Replacement Expectations Survey [37,38]. This
survey has been tested for internal consistency (Cron-
bach's alpha = 0.77) and test-retest reliability [37].
Primary outcomes
The primary outcomes will be self-reported knee pain and
physical function measured on the Western Ontario and
McMaster Universities (WOMAC) Osteoarthritis Index,
using a 5-point Likert scale (WOMAC LK3.1) [39]. The
WOMAC consists of 24 items covering three subscales:
pain (five items), stiffness (two items) and physical func-
tion (17 items). The pain and physical function subscale
will be used, each subscale transformed to a score ranging
from 0 (no pain or difficulty) to 100 (maximum pain or
difficulty). The WOMAC is a widely-used questionnaire
specifically designed to evaluate knee and hip OA [40,41].
Its clinimetric properties have also been validated in
patients undergoing TKR [42-44].
Responses on the WOMAC will also be dichotomised
according to the OMERACT-OARSI responder criteria for
OA [45], i.e. treatment responders are defined as those
participants achieving ≥20% improvement in both pain
and physical function scores and an absolute change of
≥10, or ≥50% improvement in pain or physical function
scores and an absolute change of ≥20 on the WOMAC.
Secondary outcomes
Secondary outcomes include:
￿ Quality of life (12-Item Short-Form Health Survey (SF-
12) [46], Version 2). Data from the 12 items will be used
to construct the physical and mental component sum-
mary scores. The SF-12 is a shorter questionnaire derived
from the 36-Item Short-Form Health Survey (SF-36) and
correlates well with the SF-36 (r > 0.94) [47].
￿ Priority for joint replacement surgery (Multi-attribute
Arthritis Prioritisation Tool (MAPT) [48]). The MAPT is an
11-item questionnaire that assesses the need for joint
replacement surgery. The questionnaire has high internal
consistency (alpha = 0.85), test-retest reliability (ICC =
0.89) and correlation with the WOMAC (r = 0.78) [49].
￿ Participation in leisure time physical activity will be
measured by the self-reported frequency and total dura-
tion over the past week of walking continuously, moder-
ate physical activities and vigorous physical activities [50].
Participants will be categorised as participating in suffi-
cient physical activity when more than 150 minutes of
activity is accrued in at least five separate sessions per
week [51].
￿ Fatigue ('how much of a problem has fatigue or tired-
ness been for you in the last week'). Responses will be
marked on a 100-mm visual analogue scale, with anchor
points being 'fatigue is no problem' and 'fatigue is a major
problem' [52].
￿ Use of analgesics. The use of prescription and over-the-
counter analgesics over the past week will be recorded,
and the dosage adjusted for potency using defined daily
dosage [53]
￿ Knee stability – the self-reported degree to which knee
instability (partial giving way or full giving way) affects
daily activities will be measured using the two stability
items from the Activities of Daily Living Scale of the Knee
Outcome Survey [54].
￿ Satisfaction with rehabilitation management ('how sat-
isfied have you been with your rehabilitation programme
since leaving the hospital where you had your surgery?')BMC Musculoskeletal Disorders 2009, 10:69 http://www.biomedcentral.com/1471-2474/10/69
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Responses will be required on a 6-point Likert scale, rang-
ing from 'completely dissatisfied' to 'completely satisfied'.
￿ Walking speed (50-foot (15.24 m) timed walk [55]).
Participants will be asked to walk as fast as possible within
the limits of safety, with or without a walking aid.
￿ Knee range of motion. The centre of an extendable goni-
ometer will be positioned over the lateral knee joint space
with the arms aligned with the lateral midline of the
femur using the greater trochanter as reference, and the
lateral midline of the fibula using the head of fibula and
lateral malleolus as reference [56]. Knee flexion will be
measured as an active movement in sitting. Knee exten-
sion will be measured as an active-assisted movement in
long sitting or supine with the heel supported the plinth
during the movement.
￿ Lower limb power (stair climb test). Power on stair
climb will be calculated using a formula that incorporates
body mass, the time taken to ascend 10 stairs and total
stair height [57]. This is a reliable and responsive measure
in people with knee OA undergoing TKR [17].
￿ Maximal isometric knee flexion and extension strength.
With the patient seated and the knee flexed at 90 degrees,
a 'make test' will be performed against a handheld
dynamometer, and the best of three attempts recorded.
Strength will only be measured at the 6- and 12-month
follow-up assessments because participants will be
required to comfortably achieve 90 degrees of knee flex-
ion.
The occurrence of adverse events will be sought from par-
ticipants at each follow-up assessment. Adverse events
will be defined as any musculoskeletal or cardiovascular
event resulting in medical intervention or reduced func-
tion for three or more days. An independent Data Safety
and Monitoring Committee (DSMC), comprising of
experts in clinical trials, biostatistics and rehabilitation
will be established to review data on adverse events after
300 study participants (half the planned study sample)
have completed the six-month follow-up assessment. The
DSMC will be charged with informing the study investiga-
tors if evidence emerges beyond reasonable doubt that
treatment allocation is associated with an increased risk of
serious adverse events that would be expected to change
the practice of clinicians responsible for the rehabilitation
of patients after primary TKR surgery.
Health economic outcomes
Participants will prospectively record in a patient diary the
following:
￿ presenteeism (self-reported capacity to work or perform
daily activities) [58-60]
￿ instances of absenteeism
￿ use of healthcare and community services
￿ out-of-pocket costs of community services
These data will be collected over three six-week time peri-
ods from: (i) discharge from acute care, (ii) the 6-week fol-
low-up assessment, and (iii) the 6-month (26-week)
follow-up assessment.
Presenteeism will be rated from 0% (unable to do usual
work/activities) to 100% (fully functioning). Absenteeism
is defined as days off work (including home, volunteer or
carer duties) due to TKR. The use of healthcare (e.g. visits
to medical practitioners, physiotherapists, hospitalisa-
tion) and community (e.g. meals on wheels) services will
be recorded in terms of the type of service, date of use and
number of hours/days. Costs of community services will
be the out of pocket costs incurred by participants. The use
of medication will be included as a health economic out-
come and will be collected at the time of each follow-up
assessment.
Five-year follow-up
All participants will be asked to consent to a telephone
call to complete the WOMAC, SF-12 and MAPT annually
until five years after TKR. In addition, data linkage with
the Australian National Joint Replacement Registry will be
used to verify incident primary or revision hip or knee
replacement surgeries occurring in our cohort during this
five year period.
Sample size
Based on preliminary data [35], a sample size of 600 par-
ticipants will be required. This sample size will provide
80% power of detecting a 15% difference in the propor-
tion of treatment responders (OMERACT-OARSI
responder criteria [45]) between the groups, and allows
for up to 10% cross-over of treatment allocation and a
15% loss to follow-up [61]. In addition, this sample size
will provide more than 90% power to detect clinically sig-
nificant differences in each of the continuous secondary
outcome measures.
Statistical analysis
Statistical analysis will be by intention to treat and coded
to ensure blinding to treatment allocation. For continu-
ous data, two-way repeated measures ANOVA incorporat-
ing treatment groups at the three follow-up time points (6
weeks, 6 months and 12 months) will be carried out. The
significance of any differences in dichotomous dataBMC Musculoskeletal Disorders 2009, 10:69 http://www.biomedcentral.com/1471-2474/10/69
Page 6 of 8
(page number not for citation purposes)
(OMERACT-OARSI treatment responders, proportion of
patients reporting sufficient leisure time physical activity,
number of adverse events) will be tested using generalised
estimating equations or linear mixed model. If there are
chance imbalances in baseline patient characteristics
hypothesised to influence the main outcomes, then statis-
tical techniques that allow adjustment for confounding
variables will be used as secondary analyses. If there are
more than 5% missing data, sensitivity analysis allowing
for different assumptions such as the best or worst possi-
ble scenario will also be reported for the main outcomes
of the study.
Health economic analysis
The economic evaluation will consist of a trial-based cost-
utility analysis to assess the incremental cost per quality-
of life-year (QALY) of the novel rehabilitation strategy
compared to usual care. The primary analysis will be con-
ducted from the perspective of the health sector. A second-
ary analysis will entail a societal perspective in which the
additional costs (and cost savings) associated with use of
community services, absenteeism and presenteeism will
be factored in.
In the primary analysis, costs of healthcare services will be
valued at standard rates published by the Australian Gov-
ernment: the Medical Benefits Scheme standard fees for
medical services and procedures, the Pharmaceutical Ben-
efits Scheme cost for medications and the Australian
Refined Diagnosis Related Groups (AR-DRG) cost weights
for hospital services. These will be factored with levels of
utilisation to estimate the costs of healthcare use in partic-
ipants.
In the secondary analysis, costs of community services
will be based on the self-reported costs of participants.
The costs of presenteeism will be estimated by the number
of days worked weighted by the rate of presenteeism mul-
tiplied by the average wage rate for the relevant employ-
ment category. The costs of absenteeism will be estimated
by the number of days absent from work multiplied by
the average wage rate for the relevant employment cate-
gory. For those engaged in unpaid work, the national aver-
age wage rate will be used. A separate set of cost-utility
ratios will be presented in this secondary analysis incorpo-
rating the wider costs (and cost savings) to the commu-
nity.
Health state utilities required to estimate QALY will be
based on measures obtained from the SF-12 and trans-
formed into health state utilities via the SF-6D algorithm
[62]. Although no survival difference is expected between
the two groups at 12 months, average quality of life over
12 months for each participant will be estimated and
weighted by survival up to 12 months to determine, for
each patient, a measure of QALY after TKR. Given likely
variations in the 'usual care' across sites, separate incre-
mental cost-utility ratios will be estimated for broad cate-
gories of usual care (inpatient or outpatient). Sensitivity
analysis will test uncertainty in key parameters such as the
selection of cost weights and statistical variation in quality
of life scores.
Discussion
The primary aim of the proposed pragmatic randomised
controlled trial is to compare the effectiveness and cost-
effectiveness of a novel rehabilitation strategy, consisting
of an initial home exercise programme followed by higher
intensity outpatient exercise classes, to usual rehabilitative
care in people undergoing primary TKR for OA. The trial
incorporates methodological features that have been
shown to reduce bias [63-66]. Participants will be
assigned to the novel rehabilitation strategy or usual care
by random, concealed allocation with an audit trail. Out-
comes assessments will be blinded. The nature of the
treatment precludes blinding of the therapist and the par-
ticipant, but statistical analysis will be blinded to treat-
ment allocation and will be conducted in accordance with
'intention to treat' methods.
Current evidence does not support the usual practice of
providing outpatient rehabilitation in the period immedi-
ately following discharge from the acute orthopaedic ward
after TKR in terms of improving self-reported of physical
outcomes. In light of the increasing incidence of TKR, the
need to develop clinically effective and cost-effective reha-
bilitation programs for the growing number of people
undergoing TKR surgery is paramount.
The MARKER Study is a pragmatic randomised controlled
trial designed with sufficient power to detect meaningful
clinical and economic benefits if they exist. The evaluated
rehabilitation programme is class-based, utilises only sim-
ple and widely available equipment and can therefore be
easily implemented in clinical practice. If effective, the
novel rehabilitation strategy could optimise outcomes in
people after TKR and allow substantial cost savings to
both the health sector and more widely across the com-
munity when compared to the usual, resource-intensive
one to one outpatient intervention. Furthermore, our own
observations indicate access to early outpatient rehabilita-
tion is affected by a patient's impaired physical state and
driving restrictions. A programme that allows home exer-
cise in the early recovery period followed weeks later by
outpatient rehabilitation circumvents this access problem,
thus potentially facilitating improved patient adherence
to a prescribed supervised programme.
Currently 10 large orthopaedic centres and associated
physiotherapy outpatient departments have pledged col-BMC Musculoskeletal Disorders 2009, 10:69 http://www.biomedcentral.com/1471-2474/10/69
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laboration. It is anticipated that the MARKER Study will
commence patient recruitment in early 2009. The one-
year follow-up of all study participants should be com-
pleted by the end of 2011.
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